PDX Model DetailsTM00016

Request information on the availability of this model.

PDX Model Summary

Model Details
Model ID (Previous ID)
TM00016 (BL0293F)
Initial Diagnosis
Transitional cell carcinoma
Final Diagnosis
Sarcomatoid transitional cell carcinoma
Stage/Grade
Not Specified / Grade:high
Primary Site
Bladder
Sample Site
Bladder
Tumor Type
Primary Malignancy

Publications citing this model

 Pan, C; et al. Development and Characterization of Bladder Cancer Patient-Derived Xenografts for Molecularly Guided Targeted Therapy. PLoS One 2015;10(8), p1-22. doi:10.1371/journal
Wang, M; et al. Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. 2018 FASEB 2018 Mar;32(3):1537-1549.  10.1096/fj.201700740R

Patient
Sex
Female
Age (at time of tissue collection)
77
Race/Ethnicity
White / Not Hispanic or Latino
Treatment Naïve?
Yes
Current Smoker/Former Smoker
No / Yes

Engraftment
Host Strain
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ
(aka NSG or NOD Scid gamma)
Sample Type
Surgical resection (fragment)
Engraftment Site
no data

Molecular Data (Engrafted Tumor)

Variants

Gene Expression

Platforms: RNA_Seq, hg10st

Hatched bars indicate genes with expression levels determined to be mildly affected by alignment calculations. Details.

Gene CNV

CNV Plots

Tumor Mutation Burden

 no data

Microsatellite Instability

 no data

Gene Fusion
Fusion Genes
Sample BL0293F563P0 has fusion genes MIER1--DNAI4, PKD1--NPIPP1, PTGES3L--AARSD1, AC010247.1--AC010247.2, AC068205.1--HSD17B12, MSANTD3--TMEFF1, PSG8-AS1--AC004784.1, SMURF2P1--LRRC37B, SIPA1L3--PSMD8, CEPT1--WDR47, RPSAP52--HMGA2, ANKHD1--EIF4EBP3, AL133342.1--PREX1, AL049629.2--C11orf91, ATP10D--CORIN, GON4L--AL353807.5, PCDHGB2--PCDHGA9, AMDHD1--CFAP251, LGALS17A--AC005176.1, RBM14--RBM4, SOGA3--KIAA0408, SCGB2B2--SCGB1B2P, LAMC2--AL354953.1, TVP23C--CDRT4, POLR2J2--UPK3BL1, RBM14--RBM4B, AP000347.1--ASLP1, GUSBP4--AL021368.2, CD59--C11orf91, SEPTIN7P14--PSPH, RNASEH1--AC108488.1, PCDHGB1--PCDHGA11, HLA-DMA--HLA-DMB, FAM102B--FNDC7

Model Characterization

Histology

 Summary:
P0 pathology consistent with sarcomatoid transitional cell carcinoma. P2 pathology consistent with poorly differentiated carcinoma.
Pathologist:
Dr. Regina Gandour-Edwards, University of California, Davis

Patient tumor for PDX model TM000016. High grade urothelial carcinoma invading bladder wall.
P0 tumor #563 for PDX model TM00016. Sheets of high grade urothelial carcinoma cells.

P0 tumor #563 for PDX model TM00016. Positive staining for Ki67 indicating tumor cells of human origin.
P0 tumor #563 for PDX model TM00016. Diffuse positivity for vimentin staining in tumor cells.

P2 tumor F563 ID015 for PDX model TM00016 stained for H&E.
P2 tumor F563 ID015 for PDX model TM00016 stained for AE1/AE3. Staining was positive.

P2 tumor F563 ID015 for PDX model TM00016 stained for CD45. Staining was negative.
P2 tumor F563 ID015 for PDX model TM00016 stained for Ki67. Staining was positive.

Dosing Studies

 no data

Circos Plots

Circos plot for P0 tumor #563 from PDX model TM00016